Title

Antibacterial R & D at a crossroads: We've pushed as hard as we can...now we need to start pulling!

Document Type

Article

Publication Date

2021

ISSN

1537-6591

Publisher

University of Chicago Press

Language

en-US

Abstract

In this issue of Clinical Infectious Diseases, Dheman et al [1] present an analysis by experts at the US Food and Drug Administration (FDA) of trends in antibacterial clinical development over the past 4 decades. By turns instructive and disturbing, this 40-year perspective provides insight into the impact of efforts to restore the antibacterial pipeline.

As a preview, the key messages from Dheman et al are all bad news for public health: (1) the number of new antibacterials in clinical development is (again) falling, (2) the risk of failure is rising, (3) the speed of clinical development is slowing, and (4) most large companies with the capability to market agents on a global scale have exited clinical development. Several factors have led to this state of play, as follows.

This document is currently not available here.

Share

COinS